SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma’s arm, BPCO get UKMHRA approval for Neoatricon in UK

21 Mar 2025 Evaluate

Piramal Pharma’s divisions Piramal Critical Care (PCC) and BrePco Biopharma (BPCO) have received receipt of market authorisation from U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), for the use of Neoatricon, the first pediatric strength solution for infusion of dopamine hydrochloride used in treatment for hypotension in neonates, infants, and children. PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions.

Developed by BPCO, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. 

Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or children, with off-label use remaining a common practice. The approval of Neoatricon addresses this critical gap by ensuring precise dosing, reducing the risk of under- or overdosing, and minimizing preparation time in neonatal and paediatric intensive care units (NICU & PICU), facilitating faster intervention in emergency settings.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

148.75 -0.15 (-0.10%)
20-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 935.00
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×